#United States #New York #Class Action #Gross Law Firm #Iovance Biotherapeutics

Investors of Iovance Biotherapeutics Alerted to Class Action Lawsuit

The Gross Law Firm has issued an alert to shareholders who invested in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), prompting them to consider their rights in light of a pending class action lawsuit. This notice is particularly important for investors who purchased IOVA shares during the class period, which spans from May 9, 2024, to May 8, 2025. The deadline to register for this class action and seek lead plaintiff status is July 14, 2025.

The Allegations Against Iovance

The heart of the complaint alleges that throughout the specified class period, the company's executives disseminated misleading statements about Iovance's growth potential while failing to disclose critical adverse facts. Such omissions have raised concerns about Iovance's capacity to generate demand for their treatments and manage their network of approved treatment centers effectively.

In a significant turn of events on July 25, 2024, Iovance announced second-quarter financial results that included reduced revenue forecasts for the entire fiscal year 2024. The company attributed this disappointing performance to several factors: 1) a mandatory annual maintenance period for their infrastructure, which significantly curtailed operational capacity; 2) lower than anticipated sales of Proleukin; and 3) a slow start in patient treatments at the centers.

As a direct consequence of this troubling news, Iovance's stock price suffered a drastic drop, plummeting nearly 45% in a single day. The closing share price fell from approximately $3.17 on May 8, 2025, to just $1.75 on the following day.

Next Steps for Shareholders

Shareholders are encouraged to act promptly. While the appointment as a lead plaintiff comes with no financial obligation, participating in the class action could ensure that investors are kept informed about the progress of the case. Once registered, shareholders will be enrolled in a monitoring program that provides ongoing updates about the lawsuit's status.

For those who purchased shares of IOVA during the class period, this notification could reveal significant opportunities for recovery of financial losses caused by alleged deceptive practices. To secure a place in this class action or for more information, potential plaintiffs can register through the Gross Law Firm's dedicated submission form, found at their website.

Why Choose The Gross Law Firm?

The Gross Law Firm stands out as a nationally recognized player in class action litigation, focusing particularly on protecting the rights of investors. Their commitment to legal advocacy aims to hold companies accountable for any misleading information that leads to significant investor losses. In providing this support, the firm seeks to ensure transparency and integrity within the market, embodying principles of corporate responsibility and good governance.

For any further inquiries or assistance regarding the class action lawsuit, investors can reach The Gross Law Firm directly via phone or email.

Contact Information

• - Phone: (646) 453-8903
• - Email: info@securitiesclasslaw.com
• - Address: The Gross Law Firm, 15 West 38th Street, 12th Floor, New York, NY 10018

As the deadline approaches, affected shareholders should not miss this chance to protect their investments and potentially recover losses associated with the Iovance Biotherapeutics' class action lawsuit.